Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions
Abstract
1. Introduction
2. Results
3. Discussion
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Jiang, Y.H.; Kuo, H.C. Video-urodynamic characteristics of non-neurogenic, idiopathic underactive bladder in men—A comparison of men with normal tracing and bladder outlet obstruction. PLoS ONE 2017, 12, e0174593. [Google Scholar] [CrossRef] [PubMed]
- Yang, T.H.; Chuang, F.C.; Kuo, H.C. Urodynamic characteristics of detrusor underactivity in women with voiding dysfunction. PLoS ONE 2018, 13, e0198764. [Google Scholar] [CrossRef] [PubMed]
- Hsiao, S.M.; Lin, H.H.; Kuo, H.C. Videourodynamic Studies of Women with Voiding Dysfunction. Sci. Rep. 2017, 7, 6845. [Google Scholar] [CrossRef] [PubMed]
- Dykstra, D.D.; Sidi, A.A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study. Arch. Phys. Med. Rehabil. 1990, 71, 24–26. [Google Scholar] [PubMed]
- Schurch, B.; Hauri, D.; Rodic, B.; Curt, A.; Meyer, M.; Rossier, A.B. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: A prospective study in 24 spinal cord injury patients. J. Urol. 1996, 155, 1023–1029. [Google Scholar] [CrossRef]
- Maria, G.; Destito, A.; Lacquaniti, S.; Bentivoglio, A.R.; Brisinda, G.; Albanese, A. Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 1998, 352, 625. [Google Scholar] [CrossRef]
- Phelan, M.W.; Franks, M.; Somogyi, G.T.; Yokoyama, T.; Fraser, M.O.; Lavelle, J.P.; Yoshimura, N.; Chancellor, M.B. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J. Urol. 2001, 165, 1107–1110. [Google Scholar] [CrossRef]
- Kuo, H.C. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J. Urol. 2003, 170, 1908–1912. [Google Scholar] [CrossRef] [PubMed]
- Mangera, A.; Apostolidis, A.; Andersson, K.E.; Dasgupta, P.; Giannantoni, A.; Roehrbom, C.; Novara, G.; Chapple, C. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur. Urol. 2014, 65, 981–990. [Google Scholar] [CrossRef]
- Mokhless, I.; Gaafar, S.; Fouda, K.; Shafik, M.; Assem, A. Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder. J. Urol. 2006, 176, 1767–1770. [Google Scholar] [CrossRef] [PubMed]
- Franco, I.; Landau-Dyer, L.; Isom-Batz, G.; Collett, T.; Reda, E.F. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children. J. Urol. 2007, 178, 1775–1779, discussion 1779–1780. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.H.; Wang, C.C.; Kuo, H.C. OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction—A Randomized, Double-Blind, Placebo-Controlled Study. Sci. Rep. 2016, 6, 38905. [Google Scholar] [CrossRef] [PubMed]
- Panicker, J.N.; Seth, J.H.; Khan, S.; Gonzales, G.; Haslam, C.; Kessler, T.M.; Fowler, C.J. Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler’s syndrome). BJU Int. 2016, 117, 809–813. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.H.; Jhang, J.F.; Chen, S.F.; Kuo, H.C. Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. Low Urin. Tract. Symptoms 2019, 11, 66–71. [Google Scholar] [CrossRef] [PubMed]
- Smith, C.P.; Chancellor, M.B. Emerging role of botulinum toxin in the treatment of voiding dysfunction. J. Urol. 2004, 171, 2128–2137. [Google Scholar] [CrossRef] [PubMed]
- De Sèze, M.; Petit, H.; Gallien, P.; de Seze, M.P.; Joseph, P.A.; Mazaux, J.M.; Barat, M. Botulinum a toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur. Urol. 2002, 42, 56–62. [Google Scholar]
- Mehta, S.; Hill, D.; Foley, N.; Hsieh, J.; Ethans, K.; Potter, P.; Baverstock, R.; Teasell, R.W.; Wolfs, D. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch. Phys. Med. Rehabil. 2012, 93, 597–603. [Google Scholar] [CrossRef] [PubMed]
- Smith, C.P.; Nishiguchi, J.; O’Leary, M.; Yoshimura, N.; Chancellor, M.B. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005, 65, 37–41. [Google Scholar] [CrossRef]
- Chen, Y.H.; Kuo, H.C. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. Urol. Int. 2004, 73, 156–161. [Google Scholar] [CrossRef]
- Leippold, T.; Reitz, A.; Schurch, B. Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur. Urol. 2003, 44, 165–174. [Google Scholar] [CrossRef]
- Kuo, H.C. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 2003, 61, 550–554. [Google Scholar] [CrossRef]
- Kuo, H.C. Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology 2007, 69, 57–61. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.C. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol. Urodyn. 2008, 27, 793–796. [Google Scholar] [CrossRef] [PubMed]
- Gallien, P.; Reymann, J.M.; Amarenco, G.; Nicolas, B.; de Seze, M.; Bellissant, E. Placebo-controlled, randomised, double-blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J. Neurol. Neurosurg Psychiatry 2005, 76, 1670–1676. [Google Scholar] [CrossRef] [PubMed]
- Mahfouz, W.; Karsenty, G.; Corcos, J. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: Review of indications, techniques and results: 2011 update. Can J. Urol. 2011, 18, 5787–5795. [Google Scholar] [PubMed]
- Dykstra, D.D.; Sidi, A.A.; Scott, A.B.; Pagel, J.M.; Goldish, G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988, 139, 919–922. [Google Scholar] [CrossRef]
- Liao, Y.M.; Kuo, H.C. Causes of failed urethral botulinum toxin A treatment for emptying failure. Urology 2007, 70, 763–766. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.C.; Kuo, H.C. Clinical and video urodynamic characteristics of adult women with dysfunctional voiding. J. Formos. Med. Assoc. 2014, 113, 161–165. [Google Scholar] [CrossRef] [PubMed]
- Hoeritzauer, I.; Phé, V.; Panicker, J.N. Urologic symptoms and functional neurologic disorders. Handb. Clin. Neurol. 2016, 139, 469–481. [Google Scholar]
- Jiang, Y.H.; Lee, C.L.; Jhang, J.F.; Kuo, H.C. Current pharmacological and surgical treatment of underactive bladder. Investig. Clin. Urol. 2017, 29, 187–191. [Google Scholar]
- Jiang, Y.H.; Kuo, H.C. Urothelial Barrier Deficits, Suburothelial Inflammation and Altered Sensory Protein Expression in Detrusor Underactivity. J. Urol. 2017, 197, 197–203. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.C. Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia. Int. J. Clin. Pract. 2013, 67, 1044–1049. [Google Scholar] [CrossRef] [PubMed]
- Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier, P.; Ulmsten, U.; van Kerrebroeck, P.; Victor, A.; Wein, A. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub–committee of the international continence society. Neurourol. Urodyn. 2002, 21, 167–178. [Google Scholar] [CrossRef] [PubMed]
VD Characteristics | N | Successful Outcome | Failed Outcome | p Value | |
---|---|---|---|---|---|
VD Subtype | Idiopathic VD Neurogenic VD | 80 75 | 50 (62.5%) 42 (56%) | 30 (37.5%) 33 (44%) | 0.255 |
Gender | Male Female | 54 99 | 32 (59.3%) 60 (60.6%) | 22 (40.7%) 39 (39.4%) | 0.445 |
Bladder Function | DO DU DHIC HSB | 57 59 25 14 | 36 (63.2%) 34 (57.6%) 15 (60%) 7 (50%) | 21 (36.8%) 25 (42.4%) 10 (40%) 7 (50%) | 0.819 |
Sphincter Function | DV DSD PRES | 115 237 | 70 (60.9%) 14 (60.9%) 8 (47.1%) | 45 (39.1%) 9 (39.1%) 9 (52.9%) | 0.550 |
VUDS Findings | Successful Outcome | Failed Outcome | p Value | |
---|---|---|---|---|
(n = 92) | (n = 63) | |||
Age (years) | 62 ± 18.8 | 64.7 ± 20.3 | 0.692 | |
First sensation of filling (mL) | 140.1 ± 73.0 | 132 ± 74.6 | 0.792 | |
Cystometric bladder capacity | 338 ± 142 | 267 ± 135 | 0.153 | |
Detrusor pressure (cmH2O) | 25.2 ± 25.2 | 39.0 ± 40.7 | 0.344 | |
Abdominal pressure (cmH2O) | 36.7 ± 36.3 | 34.3 ± 38.1 | 0.860 | |
Maximum flow rate (mL/s) | 6.76 ± 5.19 | 2.89 ± 3.52 | 0.031 | |
Post-void residual volume (mL) | 218 ± 5.19 | 202 ± 151 | 0.799 | |
Open bladder neck | 89 (96.7%) | 9 (14.3%) | < 0.001 | |
DU | Open BN | 34 (94.4%) | 2 (5.6%) | < 0.001 |
Tight BN | 2 (7.7%) | 24 (92.3%) | ||
Non-DU | Open BN | 55 (88.7%) | 7 (11.3%) | < 0.001 |
Tight BN | 1 (3.2%) | 30 (96.8%) |
VUDS Findings | Successful Outcome (n = 92) | Failed Outcome (n = 63) | p Value | |
---|---|---|---|---|
Bladder Function | ||||
Non-neurogenic | DU | 19 (67.9%) | 9 (32.1%) | 0.316 |
Non-DU | 31 (59.6%) | 21 (40.4%) | ||
Neurogenic | DU | 16 (48.5%) | 17 (51.5%) | 0.177 |
Non-DU | 26 (61.9%) | 16 (38.1%) | ||
Sphincter Function | ||||
Non-neurogenic | DV | 46 (62.2%) | 28 (37.8%) | 0.598 |
PRES | 4 (66.7%) | 2 (33.3%) | ||
Neurogenic | DV | 28 (53.8%) | 24 (46.2%) | 0.379 |
DSD | 14 (60.9%) | 9 (39.1%) |
Voiding Dysfunction Subtypes | FSF/FS (mL) | CBC (mL) | Pdet (cmH2O) | Pabd (cmH2O) | Qmax (mL/s) | PVR (mL) | BN Condition | ||
---|---|---|---|---|---|---|---|---|---|
Tight | Open | ||||||||
NVD-non-DU (n = 42) | S F p | 111 ± 52.3 157 ± 80.7 | 262 ± 129 381 ± 149 | 32.1 ± 26.7 26.0 ± 22.2 | 18.9 ± 18.8 26.0 ± 26.1 | 7.22 ± 6.03 3.60 ± 3.94 | 162 ± 124 285 ± 174 | 1 (8.3%) 11 (91.7%) | 26 (86.7%) 4 (13.3%) |
0.050 | 0.010 | 0.456 | 0.316 | 0.044 | 0.011 | 0.000 | |||
NVD-DU (n = 33) | S F p | 182 ± 104 230 ± 91.6 | 384 ± 150 431 ± 124 | 6.06 ± 8.65 2.53 ± 4.03 | 71.3 ± 47.0 68.2 ± 35.9 | 4.50 ± 4.26 3.76 ± 3.62 | 253 ± 143 329 ± 161 | 0 (0.0%) 16 (100%) | 16 (94.1%) 1 (5.9%) |
0.174 | 0.336 | 0.139 | 0.837 | 0.596 | 0.164 | 0.000 | |||
NNVD-non-DU (n = 53) | S F p | 132 ± 52.8 141 ± 57.0 | 350 ± 140 343 ± 109 | 39.6 ± 28.9 23.2 ± 17.5 | 29.4 ± 32.6 39.1 ± 29.7 | 8.00 ± 4.08 6.23 ± 4.57 | 176 ± 137 228 ± 129 | 1 (5.3%) 18 (94.7%) | 30 (88.2%) 4 (11.8%) |
0.576 | 0.836 | 0.013 | 0.272 | 0.144 | 0.168 | 0.000 | |||
NNVD-DU (n = 27) | S F p | 161 ± 72.4 180 ± 79.0 | 373 ± 115 360 ± 171 | 7.85 ± 8.20 7.86 ± 7.56 | 40.0 ± 27.3 34.3 ± 40.7 | 4.90 ± 5.57 3.57 ± 3.87 | 275 ± 171 274 ± 182 | 3 (33.3%) 6 (66.7%) | 17 (94.4%) 1 (5.6%) |
0.563 | 0.815 | 0.998 | 0.679 | 0.567 | 0.993 | 0.002 | |||
NVD-DV (n = 52) | S F p | 145 ± 66.4 215 ± 96.7 | 323 ± 151 450 ± 149 | 19.9 ± 25.3 9.89 ± 14.9 | 38.5 ± 35.4 49.4 ± 37.5 | 6.04 ± 6.33 3.50 ± 3.43 | 202 ± 130 328 ± 177 | 1 (5.9%) 16 (94.1) | 25 (92.6%) 2 (7.4%) |
0.013 | 0.008 | 0.139 | 0.329 | 0.129 | 0.016 | 0.000 | |||
NVD-DSD (n = 23) | S F p | 113 ± 102 168 ± 83.8 | 261 ± 134 344 ± 102 | 29.7 ± 24.8 21.8 ± 25.6 | 31.4 ± 42.5 44.6 ± 43.9 | 7.33 ± 3.74 3.91 ± 4.39 | 157 ± 124 289 ± 148 | 0 (0.0%) 8 (100%) | 15 (83.3%) 3 (16.7%) |
0.152 | 0.099 | 0.435 | 0.450 | 0.042 | 0.021 | 0.000 | |||
NNVD-DV (n = 74) | S F p | 144 ± 63.4 149 ± 66.0 | 361 ± 132 349 ± 127 | 28.1 ± 28.0 20.9 ± 17.0 | 31.4 ± 29.1 40.6 ± 32.7 | 6.92 ± 4.96 5.77 ± 4.48 | 213 ± 160 237 ± 135 | 4 (14.8%) 23 (85.2%) | 45 (93.8) 3 (6.3%) |
0.735 | 0.709 | 0.175 | 0.218 | 0.327 | 0.514 | 0.000 | |||
NNVD-NR (n = 6) | S F p | 138 ± 17.7 183 ± 38.9 | 304 ± 65.1 305 ± 134 | 5.00 ± 0.00 0.00 ± 0.00 | 85.0 ± 35.4 12.5 ± 10.6 | 3.50 ± 2.12 1.00 ± 1.41 | 250 ± 70.7 350 ± 212 | 0 (0.0%) 1 (100%) | 2 (66.7%) 1 (33.3%) |
0.275 | 0.993 | 0.218 | 0.109 | 0.300 | 0.592 | 1.000 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, Y.-K.; Kuo, H.-C. Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions. Toxins 2019, 11, 487. https://doi.org/10.3390/toxins11090487
Lee Y-K, Kuo H-C. Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions. Toxins. 2019; 11(9):487. https://doi.org/10.3390/toxins11090487
Chicago/Turabian StyleLee, Yu-Khun, and Hann-Chorng Kuo. 2019. "Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions" Toxins 11, no. 9: 487. https://doi.org/10.3390/toxins11090487
APA StyleLee, Y.-K., & Kuo, H.-C. (2019). Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions. Toxins, 11(9), 487. https://doi.org/10.3390/toxins11090487